#United States #Belgrade #Xtant Medical #OsteoFactor Pro #XTNT

Xtant Medical Reports Second Quarter 2025 Financial Results

Xtant Medical Holdings, Inc. (NYSE American: XTNT), a notable player in the global medical technology sector, has reported impressive financial performance for the second quarter ending June 30, 2025. With a focus on surgical solutions addressing spinal, orthopedic, and wound care disorders, the company achieved notable milestones that reflect its commitment to innovation and operational efficiency.

Financial Highlights

In the second quarter of 2025, Xtant Medical reported total revenue of $35.4 million, representing an 18% increase over the previous year's quarter, which recorded $29.9 million. This growth has been driven primarily by enhanced sales in orthobiologics and a licensing agreement that contributed $4.975 million in additional revenue. The company's gross margin also improved significantly, climbing to 68.6%, up from 62.1% in Q2 2024. Such financial indicators underscore the effectiveness of Xtant's strategic initiatives to streamline operations and elevate sales performance.

A spotlight on profitability reveals that Xtant achieved a net income of $3.6 million for the quarter, a notable turnaround from a net loss of $3.9 million reported in the corresponding period last year. Adjusted EBITDA for the quarter was $6.9 million, compared to an adjusted EBITDA loss of $0.6 million in Q2 2024. These results collectively position the company not just as a medical provider but as a financially stable entity poised for sustained growth.

Operational Achievements

Beyond the financial figures, Xtant has made significant strides in its operational framework. In a strategic move to concentrate on its core offerings, Xtant announced definitive agreements to divest its non-core spinal implants and associated international operations, projected to yield around $19.2 million in proceeds. This decision aligns with Xtant's vision to enhance its biologics division and utilize the proceeds for further innovation and development.

Moreover, the launch of OsteoFactor Pro™, designed as an allogeneic growth factor cocktail, signals a major advancement in bone healing techniques, reinforcing Xtant's commitment to cutting-edge solutions across orthopedic and spinal procedures. Complementing this is the introduction of Trivium™, a next-generation demineralized bone matrix allograft meant to transform standards in bone grafting practices.

Sean Browne, President and CEO of Xtant Medical, remarked on these achievements: "Our strong financial and operational results highlight our strategic emphasis on the core biologics business. This focus has allowed us to manage expenses judiciously while fostering positive cash flow. The introduction of our next-generation growth factor, OsteoFactor Pro™, establishes us as a unique entity capable of providing comprehensive solutions across all major orthobiologic categories."

Looking Ahead

As 2025 progresses, Xtant has raised its full-year revenue guidance, now predicting revenues between $131 million to $135 million, indicating a growth forecast of 11%-15% compared to 2024 figures. This upward revision comes in light of the company's positive trajectory amidst a competitive industry landscape.

Moreover, Xtant will host a conference call and webcast to discuss its financial and operational results, inviting stakeholders to engage with the leadership team directly. The call is scheduled for 8:30 AM ET on August 12, 2025, and will also be available for replay on the company's investor website.

Xtant Medical Holdings, Inc. continues to forge ahead with a mission driven by innovation and quality in medical technology. With a passionate team dedicated to improving surgical solutions, Xtant remains committed to delivering enduring value for patients and shareholders alike. For further information, please visit Xtant Medical's website.

• ---

Cautionary Statements: Forward-looking statements made in this release are subject to risks and uncertainties that could materially affect actual results. For a full exploration of these factors, please refer to the company's SEC filings.